When drugs enter the bladder, it’s only a matter of time before they are washed out.
With an innovative approach, Trigone addresses this critical problem, enabling slow drug release over time, significantly improving efficacy and patient satisfaction.
With Trigone’s drug delivery system, people suffering from bladder disorders get the relief and the effective treatment they need.
TRIGONE'S Novel Delivery System
Our Technology
Trigone’s innovative technology locally sustains the release of drugs, thereby enabling effective and safe therapy.
A bi-phasic formulation is administered inside the bladder in two stages:
PHASE A
a hydrophilic gel is instilled via a catheter into an empty bladder to facilitate the generation of a drug reservoir.
PHASE B
a hydrophobic polymeric solution containing the drugs is instilled into the gel, creating a soft spheric drug reservoir.
The soft matrix drug reservoir undergoes slow biodegradation in the presence of water, gradually releasing the drug into the urine, enabling longer exposure of the urothelium tissue to the drugs conferring effective and safe therapy.
The Benefits
Prolonged release inside the bladder for periods of days, weeks and beyond
Localized delivery system
Localized delivery system acts continuously for days & weeks
Versatile
Can be applied to a combination of drugs
Safe
Safe & well tolerated by patients
Fully biodegradable
Fully biodegradable — dissolves safely over time
Flexible
10 minutes instillation procedure
In-vitro, animal studies and human clinical trials have demonstrated the safety and efficacy of Trigone’s delivery system.
In-vitro Oxybutynin Cumulative drug amount released
5ml 1% Oxybutynin HCl formulation was instilled into 90ml artificial urine (AUF) and kept in an orbital shaker incubator at 370C, 20 rpm. 85 ml sample was withdrawn every 24 h and replaced by fresh AUF. Oxybutynin in the UAF was quantitatively determined by HPLC.
Matrix seven days post instillation inside pig’sbladder
(cystoscopy imaging)
In-vitro, animal studies and human clinical trials have demonstrated the safety and efficacy of Trigone’s delivery system.
Mean Plasma Concentration of Oxybutynin HCl
Mean plasma concentration following single intravesical administration of 5g 0.6% Oxybutynin HCl in pigs (N=3)
* N-desethyl-oxybutynin was not detected in the plasma.
Our pipeline presents highly effective and safe treatments to alleviate patients’ debilitating health burden and improve patients’ compliance.